{"organizations": [], "uuid": "2ad06e9dd8ff456e751a349b27a157acc961ac85", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/idUSL8N1RU2AT", "country": "US", "domain_rank": 408, "title": "BRIEF-OncoArendi Therapeutics To Debut On WSE On April 19", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T18:49:00.000+03:00", "replies_count": 0, "uuid": "2ad06e9dd8ff456e751a349b27a157acc961ac85"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/idUSL8N1RU2AT", "ord_in_thread": 0, "title": "BRIEF-OncoArendi Therapeutics To Debut On WSE On April 19", "locations": [], "entities": {"persons": [{"name": "oncoarendi", "sentiment": "negative"}], "locations": [{"name": "warsaw", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17 (Reuters) - ONCOARENDI THERAPEUTICS SA:\n* SAID ON MONDAY THAT WARSAW STOCK EXCHANGE (WSE) DECIDED TO INTRODUCE THE COMPANY’S SHARES AND RIGHTS TO SHARES TO TRADE ON APRIL 19\n* WSE ADMITTED THE COMPANY’S SERIES A, B, C, D AND F SHARES TO TRADE AND 2.0 MLN RIGHTS TO COMPANY’S SERIES F SHARES ON APRIL 12\n* ONCOARENDI THERAPEUTICS SAID ON MARCH 28 THAT ISSUE PRICE FOR ITS SHARES IN IPO HAS BEEN SET AT 29 ZLOTYS PER SHARE\n* COMPANY SPECIALIZES IN DEVELOPMENT AND COMMERCIALIZATION OF NEW DRUGS USED IN TREATMENT OF CANCERS AND RESPIRATORY DISEASES\n* IN DEC, CO INFORMED THAT FROM IPO PROCEEDS IT PLANS TO FINANCE ITS CURRENTLY UNDERTAKEN R&D PROJECTS AND TO FUND NEW PROJECTS\nSource text: nEM6rKG3qa\nFurther company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T18:49:00.000+03:00", "crawled": "2018-04-18T18:30:34.007+03:00", "highlightTitle": ""}